Mel Mann: Asciminib Shows Higher MMR Rates at 144 Weeks in Frontline Chronic Myeloid Leukemia
Mel Mann/X

Mel Mann: Asciminib Shows Higher MMR Rates at 144 Weeks in Frontline Chronic Myeloid Leukemia

Mel Mann, Patient Advocate, Chronic Myeloid Leukemia Survivor, shared on X:

“Asciminib Continues to show higher MMR Rates at 144 Weeks in frontline CML.

Updated ASC4FIRST Phase 3 results confirm superior major molecular response with asciminib versus investigator-selected TKIs in newly diagnosed chronic-phase CML, with a favorable safety profile and more patients remaining on treatment.

The STAMP inhibitor expands first-line options.

New cancer stories every day on YouTube.

Education only – not medical advice.”

You can also read:

Asciminib